JP2007515481A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007515481A5 JP2007515481A5 JP2006546911A JP2006546911A JP2007515481A5 JP 2007515481 A5 JP2007515481 A5 JP 2007515481A5 JP 2006546911 A JP2006546911 A JP 2006546911A JP 2006546911 A JP2006546911 A JP 2006546911A JP 2007515481 A5 JP2007515481 A5 JP 2007515481A5
- Authority
- JP
- Japan
- Prior art keywords
- azabicyclo
- oct
- oxygen
- disease
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000003118 aryl group Chemical group 0.000 claims 19
- 229910052717 sulfur Inorganic materials 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 125000004430 oxygen atom Chemical group O* 0.000 claims 9
- 125000004434 sulfur atom Chemical group 0.000 claims 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 8
- -1 oct-3-yl Chemical group 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 239000001301 oxygen Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 239000011593 sulfur Substances 0.000 claims 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 239000003205 fragrance Substances 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 238000001727 in vivo Methods 0.000 claims 4
- 239000002243 precursor Substances 0.000 claims 4
- 230000006735 deficit Effects 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 230000001713 cholinergic effect Effects 0.000 claims 2
- 230000007278 cognition impairment Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 210000000225 synapse Anatomy 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000003935 attention Effects 0.000 claims 1
- 235000019788 craving Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000005586 smoking cessation Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53164803P | 2003-12-22 | 2003-12-22 | |
| PCT/SE2004/001943 WO2005061495A1 (en) | 2003-12-22 | 2004-12-20 | Nicotinic acetylcholine receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007515481A JP2007515481A (ja) | 2007-06-14 |
| JP2007515481A5 true JP2007515481A5 (enExample) | 2008-02-07 |
Family
ID=34710243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006546911A Abandoned JP2007515481A (ja) | 2003-12-22 | 2004-12-20 | ニコチン性アセチルコリンレセプターリガンド |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070191422A1 (enExample) |
| EP (1) | EP1699787A1 (enExample) |
| JP (1) | JP2007515481A (enExample) |
| KR (1) | KR20060123365A (enExample) |
| CN (1) | CN1914200A (enExample) |
| AU (1) | AU2004303740A1 (enExample) |
| BR (1) | BRPI0417933A (enExample) |
| CA (1) | CA2550847A1 (enExample) |
| IL (1) | IL176073A0 (enExample) |
| MX (1) | MXPA06007024A (enExample) |
| NO (1) | NO20063331L (enExample) |
| SG (1) | SG149051A1 (enExample) |
| WO (1) | WO2005061495A1 (enExample) |
| ZA (1) | ZA200605024B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0000540D0 (sv) * | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| PT1791811E (pt) * | 2004-09-21 | 2010-02-23 | Astellas Pharma Inc | ¿derivados de aminoálcool |
| EP2593447B1 (de) | 2010-07-15 | 2016-08-17 | Bayer Intellectual Property GmbH | 3-pyridyl-heteroarylcarboxamidverbindungen als schädlingsbekämpfungsmittel |
| KR101928505B1 (ko) * | 2011-01-28 | 2018-12-12 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0000540D0 (sv) * | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| WO2002015662A2 (en) * | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists |
| WO2002017358A2 (en) * | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists) |
| JP2004506734A (ja) * | 2000-08-21 | 2004-03-04 | ファルマシア・アンド・アップジョン・カンパニー | 疾患治療用のキヌクリド置換ヘテロアリール部分 |
| DE10156719A1 (de) * | 2001-11-19 | 2003-05-28 | Bayer Ag | Heteroarylcarbonsäureamide |
-
2004
- 2004-12-20 EP EP04809116A patent/EP1699787A1/en not_active Withdrawn
- 2004-12-20 CA CA002550847A patent/CA2550847A1/en not_active Abandoned
- 2004-12-20 KR KR1020067012363A patent/KR20060123365A/ko not_active Withdrawn
- 2004-12-20 SG SG200809494-8A patent/SG149051A1/en unknown
- 2004-12-20 WO PCT/SE2004/001943 patent/WO2005061495A1/en not_active Ceased
- 2004-12-20 BR BRPI0417933-1A patent/BRPI0417933A/pt not_active IP Right Cessation
- 2004-12-20 MX MXPA06007024A patent/MXPA06007024A/es unknown
- 2004-12-20 JP JP2006546911A patent/JP2007515481A/ja not_active Abandoned
- 2004-12-20 AU AU2004303740A patent/AU2004303740A1/en not_active Abandoned
- 2004-12-20 US US10/583,581 patent/US20070191422A1/en not_active Abandoned
- 2004-12-20 CN CNA2004800412792A patent/CN1914200A/zh active Pending
-
2006
- 2006-05-31 IL IL176073A patent/IL176073A0/en unknown
- 2006-06-19 ZA ZA200605024A patent/ZA200605024B/en unknown
- 2006-07-18 NO NO20063331A patent/NO20063331L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003512374A5 (enExample) | ||
| JP2006507241A5 (enExample) | ||
| RU2372350C2 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ 2-(1-АЗА-БИЦИКЛО[2.2.2]ОКТ-3-ИЛ)-2,3-ДИГИДРОИЗОИНДОЛ-1-ОНА/5,6-ДИГИДРО-ФУРО[2,3-c]ПИРРОЛ-4-ОНА В КАЧЕСТВЕ ЛИГАНДОВ К АЛЬФА 7 НИКОТИНОВОМУ АЦЕТИЛХОЛИНОВОМУ РЕЦЕПТОРУ | |
| JP2007532637A5 (enExample) | ||
| AU645399B2 (en) | (-)-((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl) phenyl)-hydrazono)propanedinitrile | |
| JP2003514818A5 (enExample) | ||
| JP2003523342A5 (enExample) | ||
| JP2003513071A5 (enExample) | ||
| CN101605784B (zh) | 氮杂桥环化合物 | |
| JP2013532652A5 (enExample) | ||
| JP2003513073A5 (enExample) | ||
| RU2002118302A (ru) | Новые биарилкарбоксамиды | |
| HRP20220177T1 (hr) | Heteroaril supstituirani beta-hidroksietilamini za upotrebu u liječenju hiperglikemije | |
| RU2001122812A (ru) | Новые аралкиламины спирофуропиридинов, полезные в терапии | |
| JP2018511647A5 (enExample) | ||
| JP2001526269A5 (enExample) | ||
| ATE451373T1 (de) | N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung | |
| JP2008539195A (ja) | 新規のオキサジアゾール誘導体及びそれらの医学的使用 | |
| JP2005527588A5 (enExample) | ||
| RU2008143450A (ru) | Лиганды никотиновых ацетилхолиновых рецепторов 101 | |
| JP2015516429A5 (enExample) | ||
| JP2007515479A5 (enExample) | ||
| HRP20080175T3 (hr) | Supstituirani 2-aminotetrtalini, namijenjeni preventivnom liječenju parkinsonove bolesti | |
| JP7316672B2 (ja) | 細菌感染を予防及び処置するためのピリミジン誘導体 | |
| JP2024543973A5 (enExample) |